Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
124.46
-19.89 (-13.78%)
At close: Nov 4, 2025, 4:00 PM EST
124.55
+0.09 (0.07%)
Pre-market: Nov 5, 2025, 8:09 AM EST
Zoetis Revenue
Zoetis had revenue of $2.40B in the quarter ending September 30, 2025, with 0.50% growth. This brings the company's revenue in the last twelve months to $9.40B, up 2.68% year-over-year. In the year 2024, Zoetis had annual revenue of $9.26B with 8.33% growth.
Revenue (ttm)
$9.40B
Revenue Growth
+2.68%
P/S Ratio
5.91
Revenue / Employee
$680,942
Employees
13,800
Market Cap
54.85B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
| Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
| Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
| Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
| Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
ZTS News
- 16 hours ago - Zoetis Inc. (ZTS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 hours ago - Zoetis Stock Outlook Clouded By Rising Competitive Pressures - Benzinga
- 19 hours ago - Zoetis: No Longer A Growth Stock - Seeking Alpha
- 23 hours ago - This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps. - Barrons
- 1 day ago - Zoetis trims annual revenue forecast on muted demand for animal treatments, shares slide - Reuters
- 1 day ago - Zoetis Announces Third Quarter 2025 Results - Business Wire
- 1 day ago - Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026 - Business Wire
- 1 day ago - Zoetis: High-Quality Compounder For Patient Long-Term Dividend Growth Investors - Seeking Alpha